Results 71 to 80 of about 73,182 (252)
A carrier‐free peptide‐guided PSP@IR‐CF3 nanofiber system integrates PD‐L1 targeting and photothermal immunotherapy for enhanced cancer treatment. By revealing PTIT‐induced activation of the HSP70/AKT/mTOR pathway and incorporating mTOR inhibition, this strategy effectively overcomes therapeutic resistance and prevents tumor recurrence, providing a ...
Xinyu Zhang +11 more
wiley +1 more source
Cytotoxic T-lymphocyte associated antigen-4 (CTLA-4) tumour expression in gastric carcinoma
Background & objectives Immune checkpoint inhibitor (ICI) therapy is an emerging therapeutic strategy for several malignancies, including gastric cancer, that hinges on immune checkpoint expression by the tumour infiltrating lymphocytes (TILs).
Kottarathil, Meryl Saji +3 more
openaire +2 more sources
18F‐FGln PET/CT imaging serves as a marker of Gln uptake in hepatocellular carcinoma. Tumors with high Gln uptake drive Treg‐mediated immunosuppression and immune evasion during antitumor immunotherapy. Conversely, tumors with low Gln uptake maintain sufficient Gln in the TME, suppressing Tregs and enabling cytotoxic T cells to inhibit tumor growth ...
Yi Liu +8 more
wiley +1 more source
T cells, the Next Big Target in Axial Spondyloarthritis?
Axial spondyloarthritis (axSpA) is a chronic inflammatory disease characterized by complex immune dysregulation, with T cells playing a central role in its pathogenesis. In this review, we synthesize current knowledge on diverse T cell subsets in axSpA, their pathogenic mechanisms, and emerging therapeutic strategies targeting these cells. We highlight
Mansi K. Aparnathi, Nigil Haroon
wiley +1 more source
Objective Somatic DNMT3A mutations are the most common drivers of clonal hematopoiesis in patients with rheumatoid arthritis (RA) and have been associated with seropositive disease and increased markers of inflammation. These mutations are predominantly hypomorphic or dominant‐negative, reducing DNMT3A function.
Yunbing Shen +10 more
wiley +1 more source
The cytotoxic T-lymphocyte antigen 4 (CTLA-4) gene is a negative regulator of T lymphocyte activation and proliferation. Single nucleotide polymorphisms (SNPs) occurring on the CTLA-4 gene can modify the ability to control the proliferation of T ...
Moisés Enciso-Vargas +3 more
doaj +1 more source
Tackling cancer stemness with nanotechnology in the era of precision medicine
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo +9 more
wiley +1 more source
Association of CTLA-4 polymorphisms with hematologic malignancy susceptibility: a meta-analysis
BackgroundRecent studies have reported an association between Cytotoxic T-lymphocyte antigen-4 (CTLA-4) polymorphisms and hematologic malignancy susceptibility, while the results remain inconsistent. Hence, we performed a meta-analysis to investigate the
Xuefen Yan +3 more
doaj +1 more source
Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy
Cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) is a membrane glycoprotein expressed by activated effector T cells (Teffs) and participates in the repression of T cell proliferation, cell cycle progression and cytokine production.
Yinghao Zhao +5 more
doaj +1 more source
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen +9 more
wiley +1 more source

